10 Aug 2018

GLOBAL ULTRASOUND DEVICES MARKET ANALYZED THROUGH 2023

           A global ultrasound devices market report has added to the Research and Markets  offering. According to the “Global Ultrasound Devices Market — Segmented by Application, Technology, Type, and Geography – Growth, Trends, and Forecast (2018-2023)” report, the market is expected to register a CAGR of about 4 percent during 2018-2023. The

0
09 Aug 2018

‘18 AMPUTATION PREVENTION SYMPOSIUM: CARDIOVASCULAR SYSTEMS PRESENTS LIBERTY 360° TWO-YEAR OUTCOMES

Cardiovascular Systems Inc. , medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, presented two-year outcomes from its LIBERTY 360° study in a late-breaking presentation at the 2018 Amputation Prevention Symposium (AMP) in Chicago Aug. 8. The LIBERTY 360° study is designed

0
07 Aug 2018

MICROSOFT IS DEVELOPING A GLASSES-BASED BLOOD PRESSURE MONITOR

            Microsoft is developing new blood pressure monitoring technology called Glabella, which comes equipped on a pair of glasses that passively collects physiological data on the wearer, according to a research paper recently released by the company. The paper was written by Christian Holz, Microsoft Research in Redmond; and  Edward J.

0
01 Aug 2018

GE HEALTHCARE, LANTHEUS BEGIN A PHASE 3 CLINICAL TRIAL OF FLURPIRIDAZ TO TREAT CAD

GE Healthcare and Lantheus Holdings Inc., parent company of Lantheus Medical Imaging Inc., have started a second Phase 3 clinical trial of Flurpiridaz 18F (called the AURORA study), an investigational agent being evaluated for the detection of coronary artery disease (CAD), the most common form of heart disease.1 CAD affects an estimated

0
Patient presents with bilateral bulging varicosities
28 Jul 2018

POLIDOCANOL INJECTABLE FOAM: WHEN VEINS DON’T TAKE A STRAIGHT PATH

Patient presents with bilateral bulging varicosities   By Ajit Naidu, MD An estimated one-third of the population in Western countries has untreated venous disease.[i] Some of these individuals have lived with debilitating symptoms of venous insufficiency for a decade or more because their primary care physicians or OB/GYNs have told

0
25 Jul 2018

ECHONOUS VEIN DESIGNED TO IMPROVE FIRST-TIME STICKS

EchoNous, a Seattle provider focused on delivering intelligent medical tools, has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the EchoNous Vein, an ultrasound-based tool designed specifically for nurses to improve peripheral IV (PIV) catheter placements. Developed for usage across a wide range of patients including both adults

0
16 Jul 2018

JEFF SOINSKI INTERVIEW WITH MEDGADGET: AVINGER MAKES P.A.D. TREATMENT SAFER WITH REAL-TIME INTRAVASCULAR IMAGING

  By Michael Batista Peripheral artery disease (P.A.D.), a circulatory condition in which narrowed arteries reduce blood flow to the extremities, is projected to affect more than 21 million patients in the United States by 2020. Common treatments include balloon angioplasty, atherectomy, stenting and bypass, all of which require physicians

0
26 Jun 2018

DERMAKA HAS NEW ENHANCED NATURAL HEALING FORMULA

  Dermaka cream is an all-natural plant-based product that aids in skin healing, rejuvenation, and substantially reduces redness and bruising. Dermaka cream was developed by Ronald Bush, MD, FACS, to minimize bruising and inflammatory responses of the skin in the post-operative period. While the product has been around for several

0
26 Jun 2018

THE MARKETING BOT: HOW TO USE YOUR TIRELESS, HIGH-ROI MARKETING GENIUS

By Scott Harvey It’s been said, and it’s pretty well-accepted, that e-mail is the “killer app” that turned the Internet from an interesting technology into the behemoth it has become. There’s no question that email, and its offspring such as various messaging apps such as Facebook Messenger and WhatsApp, have

0
07 Jun 2018

OPTALYSE PE: BTG RESULTS REINFORCE SAFETY, EFFICACY OF SHORTER, LOWER DOSE EKOS THERAPY FOR PE

BTG plc highlighted OPTALYSE PE one-year trial results, presented at the International Society on Endovascular Therapy in Florida in February. The findings confirm that bilateral pulmonary embolism (PE) patients treated in as little as two hours with a total tissue plasminogen activator (tPA) dose as low as 8mg continue to

0